Početna › Akutna bifentipska leukemija › Oklahoma
Kliničke studije za Akutna bifentipska leukemija u državi Oklahoma
5 studija za Akutna bifentipska leukemija traži sudionike na lokacijama u državi Oklahoma.
Gradovi u državi Oklahoma
Službeni tekst studije (engleski)
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
- University of Oklahoma Health Sciences Center, Oklahoma City
U tijeku regrutacijaFaza 2
365 Days · Oba spola · Ažurirano 25. ruj 2026. · NCT06317662Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
- University of Oklahoma Health Sciences Center, Oklahoma City
- Saint Francis Children's Hospital, Tulsa
U tijeku regrutacijaFaza 3
365 Days – 25 Years · Oba spola · Ažurirano 25. kol 2026. · NCT03959085The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
- University of Oklahoma Health Sciences Center, Oklahoma City
U tijeku regrutacijaFaza 1/2
Do 22 godina · Oba spola · Ažurirano 25. kol 2026. · NCT04726241Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)
- Saint Francis Children's Hospital, Tulsa
U tijeku regrutacijaFaza 2
Od 1 do 18 godina · Oba spola · Ažurirano 10. kol 2026. · NCT06390319Identification of Necessary Information for Treatment Induction in Newly Diagnosed Acute Lymphoblastic Leukemia/Lymphoma
- Saint Francis Children's Hospital, Tulsa
U tijeku regrutacijaFaza 4
Od 1 do 18 godina · Oba spola · Ažurirano 14. srp 2026. · NCT06289673Iz ClinicalTrials.gov, podaci preuzeti 5. lis 2026.. Svaka studija ima svoje uvjete prihoda; tim studije odlučuje tko se može priključiti.